BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 31054264)

  • 1. Engineering antigen-specific NK cell lines against the melanoma-associated antigen tyrosinase via TCR gene transfer.
    Parlar A; Sayitoglu EC; Ozkazanc D; Georgoudaki AM; Pamukcu C; Aras M; Josey BJ; Chrobok M; Branecki S; Zahedimaram P; Ikromzoda L; Alici E; Erman B; Duru AD; Sutlu T
    Eur J Immunol; 2019 Aug; 49(8):1278-1290. PubMed ID: 31054264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TCR-NK Cells: A Novel Source for Adoptive Immunotherapy of Cancer.
    Karahan ZS; Aras M; Sütlü T
    Turk J Haematol; 2023 Feb; 40(1):1-10. PubMed ID: 36719099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
    Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
    Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
    BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors.
    Bobisse S; Rondina M; Merlo A; Tisato V; Mandruzzato S; Amendola M; Naldini L; Willemsen RA; Debets R; Zanovello P; Rosato A
    Cancer Res; 2009 Dec; 69(24):9385-94. PubMed ID: 19996290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.
    Silk JD; Abbott RJM; Adams KJ; Bennett AD; Brett S; Cornforth TV; Crossland KL; Figueroa DJ; Jing J; O'Connor C; Pachnio A; Patasic L; Peredo CE; Quattrini A; Quinn LL; Rust AG; Saini M; Sanderson JP; Steiner D; Tavano B; Viswanathan P; Wiedermann GE; Wong R; Jakobsen BK; Britten CM; Gerry AB; Brewer JE
    J Immunol; 2022 Jan; 208(1):169-180. PubMed ID: 34853077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.
    Chinnasamy N; Wargo JA; Yu Z; Rao M; Frankel TL; Riley JP; Hong JJ; Parkhurst MR; Feldman SA; Schrump DS; Restifo NP; Robbins PF; Rosenberg SA; Morgan RA
    J Immunol; 2011 Jan; 186(2):685-96. PubMed ID: 21149604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
    Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
    Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing.
    Campillo-Davo D; Fujiki F; Van den Bergh JMJ; De Reu H; Smits ELJM; Goossens H; Sugiyama H; Lion E; Berneman ZN; Van Tendeloo V
    Front Immunol; 2018; 9():2503. PubMed ID: 30464762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
    Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
    J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.
    Sensi M; Traversari C; Radrizzani M; Salvi S; Maccalli C; Mortarini R; Rivoltini L; Farina C; Nicolini G; Wölfel T
    Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5674-8. PubMed ID: 7777568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual recognition of a human cytotoxic T-cell clone for melanoma antigens.
    Kubo H; Abe J; Obata F; Nakajima H; Tsunoda M; Ogawa A; Nakayama S; Beck Y; Kohsaka T; Darrow TL; Abdel-Wahab Z; Saida T; Takiguchi M
    Cancer Res; 1996 May; 56(10):2368-74. PubMed ID: 8625313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine-induced killer cells engineered with exogenous T-cell receptors directed against melanoma antigens: enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition.
    Elia AR; Circosta P; Sangiolo D; Bonini C; Gammaitoni L; Mastaglio S; Genovese P; Geuna M; Avolio F; Inghirami G; Tarella C; Cignetti A
    Hum Gene Ther; 2015 Apr; 26(4):220-31. PubMed ID: 25758764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TCR reconstitution in Jurkat reporter cells facilitates the identification of novel tumor antigens by cDNA expression cloning.
    Aarnoudse CA; Krüse M; Konopitzky R; Brouwenstijn N; Schrier PI
    Int J Cancer; 2002 May; 99(1):7-13. PubMed ID: 11948485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A TCR-based Chimeric Antigen Receptor.
    Walseng E; Köksal H; Sektioglu IM; Fåne A; Skorstad G; Kvalheim G; Gaudernack G; Inderberg EM; Wälchli S
    Sci Rep; 2017 Sep; 7(1):10713. PubMed ID: 28878363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/γcnull mice.
    Shirakura Y; Mizuno Y; Wang L; Imai N; Amaike C; Sato E; Ito M; Nukaya I; Mineno J; Takesako K; Ikeda H; Shiku H
    Cancer Sci; 2012 Jan; 103(1):17-25. PubMed ID: 21951605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells.
    Shiozawa M; Chang CH; Huang YC; Chen YC; Chi MS; Hao HC; Chang YC; Takeda S; Chi KH; Wang YS
    BMC Immunol; 2018 Aug; 19(1):27. PubMed ID: 30075754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
    Morgan RA; Dudley ME; Yu YY; Zheng Z; Robbins PF; Theoret MR; Wunderlich JR; Hughes MS; Restifo NP; Rosenberg SA
    J Immunol; 2003 Sep; 171(6):3287-95. PubMed ID: 12960359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment.
    Grote S; Ureña-Bailén G; Chan KC; Baden C; Mezger M; Handgretinger R; Schleicher S
    Cells; 2021 Apr; 10(5):. PubMed ID: 33925968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.